kabutan
N225

64,011.34

-1.93%

TOPIX

4,028.30

-0.65%

USDJPY

154.19

-0.19%

Kabutan Concierge Closed Beta - Apply now

Sumitomo Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 11%, Exceeded Record Profit Forecast

Mon Mar 2, 2026 3:40 pm JST Revision

4506 Sumitomo Pharma Co., Ltd. 【IFRS】

Guidance Update Report

Sumitomo Pharma Co., Ltd. <4506> [TSE Prime] announced a performance revision after the market closed on March 2nd (15:40). The consolidated net income forecast for the fiscal year ending March 2026 has been revised upward 10.9%, from the previous forecast of 92.0 billion yen to 102 billion yen (compared to 23.6 billion yen in the previous period), increasing the growth rate from 3.9 times to 4.3 times. The company has further increased its previous forecast of record profits for the first time in four years.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (second half) consolidated net income has been revised upward from an expected loss of 6.86 billion yen to a profit of 3.14 billion yen (compared to a profit of 55.8 billion yen in the same period of the previous year), turning to a profit.

Kabutan News

Guidance Update

Second Half Update
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Oct - Mar, 2025 Prev 201,878M 1,843M -6,860M -17.3 0 Oct 31, 2025 IFRS
Oct - Mar, 2025 New 221,878M 11,843M 3,140M 7.9 0 Mar 2, 2026 IFRS
Revision Rate +9.9% +542.6%
Full Year Update
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Mar, 2026 Prev 429,000M 98,000M 92,000M 231.6 0 Oct 31, 2025 IFRS
Mar, 2026 New 449,000M 108,000M 102,000M 256.7 0 Mar 2, 2026 IFRS
Revision Rate +4.7% +10.2% +10.9% +10.9%

Current Period Guidance

Second Half Results
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Oct - Mar, 2024
218,083M 36,983M 50,017M 55,863M 140.6 0 May 13, 2025 IFRS
Guidance
Oct - Mar, 2025
221,878M 11,843M 3,140M 7.9 0 Mar 2, 2026 IFRS
YoY +1.7% -68.0% -94.4% -94.4%
Current Period Guidance
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Mar, 2024
314,558M -354,859M -323,114M -314,969M -792.8 0 May 14, 2024 IFRS
Mar, 2025
398,832M 28,804M 17,611M 23,634M 59.5 0 May 13, 2025 IFRS
Guidance
Mar, 2026
449,000M 108,000M 102,000M 256.7 0 Mar 2, 2026 IFRS
YoY +12.6% +274.9% +331.6% +331.6%